Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Raloxifene: a selective estrogen receptor modulator.

J A Scott1, C C Da Camara, J E Early

  • 1Duke/Southern Regional Area Health Education Center, Fayetteville, North Carolina 28304, USA.

American Family Physician
|October 3, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Worker risk from ultrasonicator aerosolization in medical device reprocessing: a particulate and bio-burden approach.

The Journal of hospital infection·2025
Same author

Impact of postpartum hospital length of stay on infant gut microbiota: a comprehensive analysis of vaginal and caesarean birth.

The Journal of hospital infection·2024
Same author

Brain Charts for the Rhesus Macaque Lifespan.

bioRxiv : the preprint server for biology·2024
Same author

High-content phenotypic screening identifies novel chemistries that disrupt mosquito activity and development.

Pesticide biochemistry and physiology·2022
Same author

What factors shape surgical access in West Africa? A qualitative study exploring patient and provider experiences of managing injuries in Sierra Leone.

BMJ open·2021
Same author

Twenty-first century droughts have not increasingly exacerbated fire season severity in the Brazilian Amazon.

Scientific reports·2021

Raloxifene selectively targets estrogen receptors, benefiting bone and cholesterol while opposing effects in the uterus and breast. This selective estrogen receptor modulator (SERM) shows promise for osteoporosis prevention.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Bone Metabolism

Background:

  • Selective estrogen receptor modulators (SERMs) offer targeted therapeutic effects.
  • Raloxifene exhibits tissue-specific estrogen-agonistic and antagonistic properties.
  • Understanding SERM-mediated effects is crucial for managing menopausal health and bone density.

Purpose of the Study:

  • To review the pharmacological profile of raloxifene.
  • To evaluate its efficacy in osteoporosis prevention and its impact on lipid metabolism.
  • To assess its potential benefits and risks concerning cardiovascular disease, breast, and endometrial cancer.

Main Methods:

  • Review of existing clinical studies and pharmacological data.
  • Analysis of raloxifene's effects on bone mineral density and lipid profiles.

Related Experiment Videos

  • Examination of adverse event data, including thromboembolic events and common side effects.

    • Main Results:

    • Raloxifene increases bone mineral density and lowers total and LDL cholesterol.
    • Common side effects include hot flushes and leg cramps; an increased risk of thromboembolic events is noted.
    • Raloxifene is FDA-approved for osteoporosis prevention, but fracture risk and cardiovascular protection require further investigation.

    Conclusions:

    • Raloxifene provides beneficial estrogenic effects on bone and lipids with tissue selectivity.
    • Its role in reducing fracture risk, cardiovascular events, and cancer requires ongoing research.
    • Raloxifene represents a targeted approach to managing postmenopausal health concerns.